Anteris Technologies Global Corp. (“ATGC”) today announced the
pricing of its initial public offering of 14,800,000 shares of its
common stock (“Common Stock”) in the U.S. (the “Offering”), at an
initial public offering price of $6.00 per share. The shares are
expected to begin trading on the Nasdaq Global Market on December
13, 2024 under the ticker symbol "AVR." The Offering is expected to
close on December 16, 2024, subject to customary closing
conditions.
All shares of Common Stock to be sold in the Offering are being
sold by ATGC. In addition, ATGC has granted the underwriters a
30-day option to purchase up to an additional 2,220,000 shares of
Common Stock from ATGC at the initial public offering price, less
underwriting discounts and commissions.
ATGC intends to use the net proceeds to it from the Offering,
together with its existing cash and cash equivalents, primarily for
the ongoing development of its DurAVR® transcatheter heart valve
(“DurAVR® THV”) and the preparation and enrollment of a randomized
global pivotal study of DurAVR® THV for treating severe aortic
stenosis, with the remainder for working capital and other general
corporate purposes determined from time to time, including the
repayment of amounts owed under its convertible note facility. TD
Cowen, Barclays and Cantor are acting as joint book-running
managers for the Offering, with Lake Street Capital Markets acting
as lead manager.
Following the Offering, ATGC intends to list its CHESS
Depositary Interests (“CDIs”) (representing underlying shares of
Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the
Australian Securities Exchange (“ASX”) under the symbol “AVR.”
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and was declared
effective on December 12, 2024. The Offering is being made only by
means of a prospectus. Copies of the final prospectus relating to
the Offering, when available, may be obtained from: TD Securities
(USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by
telephone at (855) 495-9846 or by e-mail at
TD.ECM_Prospectus@tdsecurities.com; Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood,
NY 11717, by telephone at (888) 603-5847 or by e-mail at
Barclaysprospectus@broadridge.com; or Cantor Fitzgerald & Co.,
110 East 59th Street, 6th Floor, New York, NY 10022, by telephone
at (212) 915-1800 or by e-mail at prospectus@cantor.com.
This press release is for informational purposes only and does
not constitute an offer to sell or the solicitation of an offer to
buy any securities, and shall not constitute an offer, solicitation
or sale of securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. As disclosed in the registration statement, the
underwriters may engage in stabilizing actions or related
activities in connection with the Offering.
About ATGC
ATGC was incorporated on January 29, 2024 for the purpose of
reorganizing the operations of Anteris Technologies Ltd
(“Anteris”), an Australian public company originally registered in
Western Australia, Australia and listed on the ASX, into a
structure whereby the ultimate parent company will be a Delaware
corporation.
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercializing
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA (a MedTech hub), Anteris
is science-driven, with an experienced team of multidisciplinary
professionals delivering potentially transformative solutions to
structural heart disease patients.
Anteris’ lead product, DurAVR®, is a transcatheter heart valve
for treating aortic stenosis. It is the first transcatheter aortic
valve replacement to use a single piece of bioengineered tissue.
This biomimetic valve is uniquely shaped to mimic the performance
of a healthy human aortic valve.
DurAVR® THV is made using ADAPT® tissue, Anteris’ patented
anti-calcification tissue technology. ADAPT® tissue has been used
clinically for over 10 years and distributed for use in over 55,000
patients worldwide.
The ComASUR® Delivery System was designed to provide controlled
deployment and accurate placement of the DurAVR® THV with
balloon-expandable delivery, designed to achieve precise alignment
with the heart’s native commissures to achieve ideal valve
positioning.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include all statements that are not
historical facts. Forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,”
“strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,”
“should,” “could,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include any statements regarding the
completion of the Offering, commencement of trading of the Common
Stock on Nasdaq and the CDIs on the ASX, the anticipated use of the
net proceeds of the Offering, and that the underwriters may engage
in stabilizing actions or related activities in connection with the
Offering. These forward-looking statements are subject to a number
of risks, uncertainties, and assumptions, including those described
under “Risk Factors” in ATGC’s registration statement relating to
the Offering. Readers are cautioned not to put undue reliance on
forward-looking statements, and except as required by law, neither
ATGC or Anteris assume any obligation to update any of these
forward-looking statements to conform these statements to actual
results or revised expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241212146897/en/
For more information: Investor Relations
investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310
| +61 7 3152 3200
Investor Relations (US) Malini Chatterjee, Ph.D.
Blueprint Life Science Group +1 917 330 4269
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
